Forth Tx Debuts with Sofinnova’s Support to Transform Fibrosis Treatment Forth Therapeutics (Forth Tx), a biotechnology company pioneering next-generation precision therapeutics for fibrosis, officially launches today with significant backing from…
BioClec Launches to Transform Alzheimer’s Treatment with Sofinnova’s Backing BioClec, a pioneering biotechnology company dedicated to revolutionizing treatments for Alzheimer’s disease, has officially launched. The company emerges from Biovelocita II,…
Sofinnova Partners’ Biotech Fund Exceeds Target at €165M Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm with offices in Paris, London, and Milan, has announced the final…
Protembis Forms Scientific Advisory Board of Leading Heart Experts Protembis, a privately-held cardiovascular medical device company, has announced the establishment of a Scientific Advisory Board (SAB) to provide strategic guidance…
ClearNote Health’s Avantect® Pancreatic Cancer Test Now Covered by Claritev’s National PPO Networks ClearNote Health, a company dedicated to advancing early detection of some of the deadliest cancers, has announced…
LGM Pharma Expands U.S. Drug Manufacturing with $6M Investment in Advanced Dosage Capabilities LGM Pharma, a leading provider of tailored API and CDMO services across the entire drug product lifecycle,…
PharmaCord and Mercalis Merge to Build Next-Gen Biopharma Platform PharmaCord and Mercalis, two leading providers of patient access and commercialization services for the biopharmaceutical industry, have announced a strategic merger…
Shift Bioscience Strengthens Leadership Team to Drive Innovation in Rejuvenation Therapeutics Shift Bioscience, a pioneering biotech company harnessing AI-powered virtual cell technology to combat age-related diseases, has announced the appointment…
New Data Reinforce the Positive Impact of Exact Sciences’ Oncotype DX® Test on Patient Care and Healthcare Efficiency Exact Sciences, a global leader in cancer screening and diagnostic solutions, has…
Hudson Therapeutics Launches Phase 2b Part 2 Trial for NuGel Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today the initiation of Phase 2b Part 2 of its clinical trial…
Merck Opens New Facility to Boost Vaccine Production Capacity Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has officially opened a new $1 billion, 225,000-square-foot…
Pharma Industry Urges Joint Action on Growing Chronic Disease Burden Ahead of a key UN milestone, the global pharmaceutical industry has launched a Call to Action to drive collective efforts…